Identification

Name
Chlorprothixene
Accession Number
DB01239  (APRD00718)
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

Structure
Thumb
Synonyms
  • Alpha-Chlorprothixene
  • Chlorprothixen
  • Chlorprothixine
  • Chlorprotixen
  • Chlorprotixene
  • Chlorprotixine
  • Chlothixen
International/Other Brands
Clothixen (Yoshitomi) / Cloxan (Orion) / Taractan (Roche)
Categories
UNII
9S7OD60EWP
CAS number
113-59-7
Weight
Average: 315.86
Monoisotopic: 315.084847978
Chemical Formula
C18H18ClNS
InChI Key
WSPOMRSOLSGNFJ-VGOFMYFVSA-N
InChI
InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7+
IUPAC Name
[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]dimethylamine
SMILES
[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2

Pharmacology

Indication

For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.

Structured Indications
Not Available
Pharmacodynamics

Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency.

Mechanism of action

Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
AD(3) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2B
antagonist
Human
A5-hydroxytryptamine receptor 2C
antagonist
Human
UHistamine H1 receptor
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Incomplete bioavailability.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic

Route of elimination
Not Available
Half life

8 to 12 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineChlorprothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineChlorprothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorprothixene.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorprothixene.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorprothixene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorprothixene.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Amantadine.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorprothixene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amperozide.Experimental
AmphetamineChlorprothixene may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorprothixene.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azaperone.Investigational, Vet Approved
AzelastineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorprothixene.Approved
BenzphetamineChlorprothixene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benzyl alcohol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorprothixene.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorprothixene.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorprothixene.Approved, Investigational
BuprenorphineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorprothixene.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorprothixene.Approved
CanertinibThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Canertinib.Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorprothixene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorprothixene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorphenamine.Approved
ChlorphentermineChlorprothixene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorprothixene.Approved, Vet Approved
ClemastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clidinium.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clonazepam.Approved, Illicit
ClopenthixolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clothiapine.Experimental
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorprothixene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorprothixene.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorprothixene.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.Approved
DetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorprothixene.Approved, Vet Approved
DextroamphetamineChlorprothixene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorprothixene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorprothixene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorprothixene.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Diethyl ether.Experimental
DiethylpropionChlorprothixene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorprothixene.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorprothixene.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorprothixene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorprothixene.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorprothixene.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorprothixene.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorprothixene.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorprothixene.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorprothixene.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorprothixene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorprothixene.Approved
EthanolChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.Approved
EzogabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.Approved, Illicit, Investigational, Vet Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorprothixene.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlorprothixene.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorprothixene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorprothixene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorprothixene.Approved, Illicit, Investigational
GepefrineChlorprothixene may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorprothixene.Approved, Illicit, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hexobarbital.Approved
HydrocodoneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.Approved, Illicit
HydroxyamphetamineChlorprothixene may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Iloperidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indiplon.Investigational
Iofetamine I-123Chlorprothixene may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorprothixene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorprothixene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ketobemidone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorprothixene.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorprothixene.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorprothixene.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorprothixene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorprothixene.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorprothixene.Approved, Investigational
LisdexamfetamineChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Chlorprothixene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorprothixene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorprothixene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorprothixene.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorprothixene.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorprothixene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Melperone.Approved, Investigational
MephedroneChlorprothixene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineChlorprothixene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Meptazinol.Experimental
MequitazineChlorprothixene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineChlorprothixene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorprothixene.Approved
MethotrimeprazineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorprothixene.Approved, Investigational, Vet Approved
MethoxyphenamineChlorprothixene may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorprothixene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.Approved, Investigational
MetyrosineChlorprothixene may increase the sedative activities of Metyrosine.Approved
MidomafetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Chlorprothixene.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational
MirtazapineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAChlorprothixene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Molindone.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorprothixene.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorprothixene.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorprothixene.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorprothixene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorprothixene.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nortriptyline.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorprothixene.Approved
OpiumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Opium.Approved, Illicit
OrphenadrineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorprothixene.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorprothixene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorprothixene.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorprothixene.Approved
ParaldehydeChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorprothixene.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
PerazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorprothixene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorprothixene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.Approved
PhenibutThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenibut.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenoxyethanol.Approved
PhentermineChlorprothixene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorprothixene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pizotifen.Approved
PramipexoleChlorprothixene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorprothixene.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorprothixene.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorprothixene.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorprothixene.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorprothixene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorprothixene.Approved
PSD502The risk or severity of adverse effects can be increased when Chlorprothixene is combined with PSD502.Investigational
PseudoephedrineChlorprothixene may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorprothixene.Approved, Illicit
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorprothixene.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorprothixene.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.Approved, Withdrawn
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorprothixene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ritanserin.Investigational
RitobegronChlorprothixene may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorprothixene.Approved
RomifidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Romifidine.Vet Approved
RopiniroleChlorprothixene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene.Approved
RotigotineChlorprothixene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorprothixene.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorprothixene.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Chlorprothixene.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
StiripentolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Chlorprothixene.Approved, Investigational
SuvorexantChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorprothixene.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorprothixene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorprothixene.Approved
TetracaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrodotoxin.Investigational
ThalidomideChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorprothixene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorprothixene.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorprothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorprothixene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorprothixene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorprothixene.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorprothixene.Approved, Investigational
VeraliprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Chlorprothixene.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorprothixene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorprothixene.Approved, Investigational
ZolpidemChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorprothixene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorprothixene.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to Merck & Co., Inc. Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.

US3046283
General References
Not Available
External Links
KEGG Drug
D00790
KEGG Compound
C07953
PubChem Compound
667466
PubChem Substance
46508957
ChemSpider
580848
BindingDB
50130257
ChEBI
50932
ChEMBL
CHEMBL90125
Therapeutic Targets Database
DAP000833
PharmGKB
PA164781400
Wikipedia
Chlorprothixene
ATC Codes
N05AF03 — Chlorprothixene
MSDS
Download (63.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153-154Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to Merck & Co., Inc. Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.
water solubility0.295 mg/LNot Available
logP5.18HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.000366 mg/mLALOGPS
logP5.42ALOGPS
logP5.07ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.66 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9899
Blood Brain Barrier+0.95
Caco-2 permeable+0.7404
P-glycoprotein substrateSubstrate0.8042
P-glycoprotein inhibitor IInhibitor0.8407
P-glycoprotein inhibitor IIInhibitor0.8884
Renal organic cation transporterInhibitor0.72
CYP450 2C9 substrateNon-substrate0.7199
CYP450 2D6 substrateSubstrate0.6845
CYP450 3A4 substrateSubstrate0.7096
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.768
Ames testNon AMES toxic0.7084
CarcinogenicityNon-carcinogens0.8714
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity3.1665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8117
hERG inhibition (predictor II)Inhibitor0.7373
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.22 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiopyrans
Sub Class
1-benzothiopyrans
Direct Parent
Thioxanthenes
Alternative Parents
Diarylthioethers / Benzenoids / Aryl chlorides / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Thioxanthene / Diarylthioether / Aryl thioether / Aryl chloride / Aryl halide / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amine, thioxanthenes (CHEBI:3651)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Froimowitz M, Cody V: Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2219-27. [PubMed:8101879]
  2. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565]
  3. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H: Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. doi: 10.1016/j.bmcl.2008.09.012. Epub 2008 Sep 7. [PubMed:19091563]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565]
Details
3. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Antkiewicz-Michaluk L: The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm. 1986 Jul-Aug;38(4):359-70. [PubMed:3774629]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol. 1987 Nov 10;143(2):279-82. [PubMed:2891550]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Details
7. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:58